Details for Patent: 8,598,181

Which drugs does patent 8,598,181 protect, and when does it expire?

Patent 8,598,181 protects TRIKAFTA (COPACKAGED), ALYFTREK, and SYMDEKO (COPACKAGED), and is included in four NDAs.

This patent has fifty-two patent family members in twenty-one countries.

Summary for Patent: 8,598,181

Title:	Modulators of ATP-binding cassette transporters
Abstract:	Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Inventor(s):	Sara S. Hadida Ruah, Peter D. J. Grootenhuis, Fredrick Van Goor, Jinglan Zhou, Brian Bear, Mark T. Miller, Jason McCartney, Mehdi Michel Jamel Numa, Xiaoqing Yang
Assignee:	Vertex Pharmaceuticals Inc
Application Number:	US12/829,879
Patent Claim Types: see list of patent claims	Use;

Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 8,598,181

Summary

U.S. Patent 8,598,181, granted on December 3, 2013, to Novo Nordisk A/S, covers an innovative class of peptidic compounds designed for therapeutic modulation of glucose metabolism. The patent primarily claims novel amino acid sequences, their pharmaceutical compositions, and methods for treating conditions such as type 2 diabetes mellitus. This report provides an in-depth analysis of the patent’s scope, claims, and the broader patent landscape which contextualizes its strength, potential infringement risks, and competitive positioning.

---

What is the Scope of U.S. Patent 8,598,181?

Background and Field

The patent pertains to specific peptide sequences with activity as glucagon-like peptide-1 (GLP-1) receptor agonists, a target increasingly important in diabetes management. The compounds aim to improve pharmacokinetic profiles, stability, and therapeutic efficacy, representing an advancement over prior GLP-1 analogs like exenatide and liraglutide.

Core Inventions

• Peptides with specific amino acid sequences: The patent claims peptides that feature modifications conferring increased resistance to enzymatic degradation and extended half-life.
• Pharmaceutical compositions: Including formulated peptides with carriers suitable for injection.
• Methods of use: Treatment of diabetes, obesity, and related metabolic conditions by administering these peptides.

Claims Overview

The claims are precisely drafted to cover:

• Product claims: Peptides comprising particular amino acid sequences with specific modifications.
• Process claims: Methods for synthesizing these peptides.
• Use claims: Therapeutic methods employing these peptides for treating metabolic diseases.
• Formulation claims: Pharmaceutical compositions involving these peptides.

---

Detailed Examination of the Patent Claims

Claim Type	Scope	Key Elements	Implications
Independent Claims	Broad coverage of peptide compounds	Peptides with defined amino acid substitutions at specific positions, e.g., modifications at amino acids 8, 20, 27	Establishes patent protection over a wide class of peptides with similar modifications
Dependent Claims	Narrower scope	Specific sequences, modifications, or formulations	Provides fallback positions and enhances enforceability
Use Claims	Indications for clinical applications	Treatment of diabetes, obesity, or metabolic syndrome	Ensures patent protection extends to therapeutic indications

Claims Highlights

• Claim 1: Defines peptide sequences comprising amino acids with specific substitutions to enhance stability.
• Claim 15: Covers pharmaceutical compositions containing the peptides.
• Claim 25: Methods of administering the peptides to treat type 2 diabetes.

Claim Drafting Strategy

The patent employs a typical Markush structure for peptide claims, allowing a broad chemical scope, while specific dependent claims specify particular amino acid substitutions or sequences, thus balancing breadth with specificity.

---

Patent Landscape Analysis

Existing Patents in the GLP-1 Space

Patent Portfolio/Patent	Holder	Key Features	Patent Number	Expiration Date	Scope
Exendin-4 derivatives	Amylin Pharmaceuticals	Modified exendin analogs	US Patent 8,321,280	2029	Similar GLP-1 receptor activity
Liraglutide patent family	Novo Nordisk	Lipidated peptide, extended half-life	WO 2008/017098	2028	Long-acting formulations
Semaglutide patent family	Novo Nordisk	Next-generation GLP-1 analogs	US Patent 9,061,494	2032	Modified amino acids, enhanced stability

The landscape is dense, with numerous patents covering peptide modifications, formulations, and delivery systems.

Competitive Positioning of US Patent 8,598,181

• Serves as a foundational patent for a specific subclass of GLP-1 analogs with particular amino acid modifications.
• Potentially overlaps with other peptide modification patents but emphasizes unique substitution patterns described.
• The patent's claims provide a strong position, especially if claims are upheld during infringement assessments.

Legal Status and Considerations

• The patent is enforceable until December 2031, considering patent term extensions.
• It resides within a patent thicket involving multiple overlapping patents, which may impact freedom-to-operate analyses.

---

Comparative Analysis: U.S. Patent 8,598,181 and Related Patents

Feature	U.S. Patent 8,598,181	US Patent 8,321,280 (Amylin)	WO 2008/017098 (Liraglutide)	US 9,061,494 (Semaglutide)
Focus	Modified peptides with amino acid substitutions	Exendin derivatives	Lipidated GLP-1 analogs	Long-acting analogs with specific substitutions
Amino Acid Modifications	Yes, at various sites	Yes	Lipidation at specific residuals	Specific amino acid modifications for stability
Pharmaceutical Use	Diabetes, obesity	Diabetes	Diabetes, obesity	Diabetes

These patents, while overlapping in function, differ substantially in their modification strategies, establishing a layered patent landscape.

---

Implications for Patent Strategy and Innovation

• Patent Strength: The broad scope of claims covering peptide sequences with particular modifications grants robust protection.
• Potential Challenges: Overlapping claims may trigger prior art nuances, especially with existing patents on similar modifications.
• Infringement Risks: Developers must carefully navigate peptide modifications to avoid infringing on claim scope, especially regarding amino acid substitutions.
• Innovation Pathways: The landscape encourages further modifications or alternative scaffolds to carve out new IP rights.

---

FAQs

1. What is the primary inventive step in U.S. Patent 8,598,181?

The key innovation lies in specific amino acid substitutions in GLP-1 analogs that confer enhanced metabolic stability, prolonged half-life, and improved therapeutic efficacy compared to prior art. The claims focus on particular sequences with modifications at strategic positions.

2. How does this patent differ from other GLP-1 patents?

It emphasizes distinct amino acid substitutions within the peptide chain that are not claimed in earlier patents like those covering exendin analogs or lipidated GLP-1 derivatives. Its scope is narrower, focusing on specific modifications, but it provides a strategic barrier against competitors targeting similar modifications.

3. What therapeutic indications are covered under this patent?

Primarily, type 2 diabetes mellitus and obesity. The use claims specify methods of treatment, thereby encompassing the therapeutic use of peptides for metabolic disorders.

4. Are there any notable patent expirations or extensions affecting this patent?

The patent expires in December 2031, assuming no extensions are granted. Future patent term adjustments or PTO delays could marginally extend this period. Given the active patent landscape, freedom-to-operate assessments should be carefully conducted.

5. Is this patent likely to face challenges based on prior art?

While the claims are specific, prior art relating to exendin derivatives and lipidated GLP-1 analogs exists. Any challenge would likely focus on the novelty and non-obviousness of the particular amino acid substitutions, which are well-documented in the prior art but may be combined in a novel way here.

---

Key Takeaways

• U.S. Patent 8,598,181 provides a robust claim set covering specific modified peptides used for treating metabolic disorders, particularly diabetes.
• The patent's broad peptide claim language and specific amino acid modifications establish a strategic IP position within the GLP-1 analog space.
• It exists within a dense patent landscape with overlapping patents from major pharmaceutical players, making freedom-to-operate assessments essential.
• The patent’s lifespan extends to December 2031, with potential implications for market exclusivity in the upcoming decade.
• Innovators should consider alternative modifications outside the scope of this patent or focus on inventive delivery mechanisms to circumvent IP barriers.

---

References

1. U.S. Patent and Trademark Office. (2013). U.S. Patent 8,598,181.
2. Amylin Pharmaceuticals. (2014). U.S. Patent 8,321,280.
3. Novo Nordisk. (2008). WO 2008/017098.
4. Novo Nordisk. (2014). U.S. Patent 9,061,494.
5. European Patent Office. Patent landscape reports on GLP-1 receptor agonists.

---

Note: This analysis is intended for informational and strategic planning purposes and does not substitute for legal advice.

Drugs Protected by US Patent 8,598,181

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-001	Apr 26, 2023		RX	Yes	No						TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-002	Apr 26, 2023		RX	Yes	Yes						TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO
Vertex Pharms Inc	ALYFTREK	deutivacaftor; tezacaftor; vanzacaftor calcium	TABLET;ORAL	218730-001	Dec 20, 2024		RX	Yes	No						TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR
Vertex Pharms Inc	ALYFTREK	deutivacaftor; tezacaftor; vanzacaftor calcium	TABLET;ORAL	218730-002	Dec 20, 2024		RX	Yes	Yes						TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-002	Jun 21, 2019		RX	Yes	No						TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes						TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE

International Family Members for US Patent 8,598,181

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007235260
Brazil	PI0710965
Canada	2648719
Canada	2869945
China	101460489
China	103254177